ANANDA Posts Update On Its Clinical Trial Of CBD Drug For The Treatment Of Opioid Use Disorder

ANANDA Scientific Inc., a research focused bio-pharmaceutical company revealed the first patient enrolled in the clinical trial evaluating Nantheia ATL5, an investigational drug using CBD in ANANDA's proprietary delivery as an adjunctive treatment for opioid use disorder.

This trial is being led by principal investigators Edythe London, Ph.D., distinguished professor of psychiatry and biobehavioral sciences as well as molecular and medicinal pharmacology at the Semel Institute, Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D., professor of psychiatry and biobehavioral sciences at the Semel Institute, Geffen School of …

Full story available on Benzinga.com

ANANDA Posts Update On Its Clinical Trial Of CBD Drug For The Treatment Of Opioid Use Disorder on Benzinga